ALKERMES PLC (ALKS) Fundamental Analysis & Valuation

NASDAQ:ALKS • IE00B56GVS15

Current stock price

27.2 USD
-0.45 (-1.63%)
At close:
27.37 USD
+0.17 (+0.63%)
Pre-Market:

This ALKS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. ALKS Profitability Analysis

1.1 Basic Checks

  • In the past year ALKS was profitable.
  • ALKS had a positive operating cash flow in the past year.
  • In multiple years ALKS reported negative net income over the last 5 years.
  • In the past 5 years ALKS always reported a positive cash flow from operatings.
ALKS Yearly Net Income VS EBIT VS OCF VS FCFALKS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M

1.2 Ratios

  • ALKS has a better Return On Assets (9.72%) than 93.44% of its industry peers.
  • With an excellent Return On Equity value of 13.28%, ALKS belongs to the best of the industry, outperforming 93.63% of the companies in the same industry.
  • ALKS's Return On Invested Capital of 10.90% is amongst the best of the industry. ALKS outperforms 94.21% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for ALKS is in line with the industry average of 19.54%.
  • The 3 year average ROIC (18.21%) for ALKS is well above the current ROIC(10.90%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA 9.72%
ROE 13.28%
ROIC 10.9%
ROA(3y)14.74%
ROA(5y)6.76%
ROE(3y)22.64%
ROE(5y)9.68%
ROIC(3y)18.21%
ROIC(5y)N/A
ALKS Yearly ROA, ROE, ROICALKS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10 20

1.3 Margins

  • ALKS's Profit Margin of 16.37% is amongst the best of the industry. ALKS outperforms 92.28% of its industry peers.
  • ALKS has a better Operating Margin (17.21%) than 93.24% of its industry peers.
  • ALKS has a Gross Margin of 86.69%. This is amongst the best in the industry. ALKS outperforms 88.80% of its industry peers.
  • ALKS's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 17.21%
PM (TTM) 16.37%
GM 86.69%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.55%
GM growth 5Y0.92%
ALKS Yearly Profit, Operating, Gross MarginsALKS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 60 80

7

2. ALKS Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), ALKS is creating value.
  • Compared to 1 year ago, ALKS has more shares outstanding
  • Compared to 5 years ago, ALKS has more shares outstanding
  • ALKS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ALKS Yearly Shares OutstandingALKS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
ALKS Yearly Total Debt VS Total AssetsALKS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B

2.2 Solvency

  • ALKS has an Altman-Z score of 5.26. This indicates that ALKS is financially healthy and has little risk of bankruptcy at the moment.
  • ALKS's Altman-Z score of 5.26 is fine compared to the rest of the industry. ALKS outperforms 73.94% of its industry peers.
  • There is no outstanding debt for ALKS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 5.26
ROIC/WACC1.42
WACC7.7%
ALKS Yearly LT Debt VS Equity VS FCFALKS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B 1.5B

2.3 Liquidity

  • ALKS has a Current Ratio of 3.55. This indicates that ALKS is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 3.55, ALKS is in line with its industry, outperforming 41.51% of the companies in the same industry.
  • ALKS has a Quick Ratio of 3.19. This indicates that ALKS is financially healthy and has no problem in meeting its short term obligations.
  • ALKS has a worse Quick ratio (3.19) than 61.20% of its industry peers.
Industry RankSector Rank
Current Ratio 3.55
Quick Ratio 3.19
ALKS Yearly Current Assets VS Current LiabilitesALKS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

5

3. ALKS Growth Analysis

3.1 Past

  • The earnings per share for ALKS have decreased strongly by -40.76% in the last year.
  • ALKS shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 31.92% yearly.
  • Looking at the last year, ALKS shows a decrease in Revenue. The Revenue has decreased by -5.25% in the last year.
  • Measured over the past years, ALKS shows a small growth in Revenue. The Revenue has been growing by 7.28% on average per year.
EPS 1Y (TTM)-40.76%
EPS 3Y71.6%
EPS 5Y31.92%
EPS Q2Q%-72.38%
Revenue 1Y (TTM)-5.25%
Revenue growth 3Y9.9%
Revenue growth 5Y7.28%
Sales Q2Q%-10.57%

3.2 Future

  • The Earnings Per Share is expected to grow by 31.80% on average over the next years. This is a very strong growth
  • ALKS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.16% yearly.
EPS Next Y-135.86%
EPS Next 2Y-28.08%
EPS Next 3Y-2.65%
EPS Next 5Y31.8%
Revenue Next Year21.99%
Revenue Next 2Y12.92%
Revenue Next 3Y10.71%
Revenue Next 5Y11.16%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ALKS Yearly Revenue VS EstimatesALKS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1B 2B 3B
ALKS Yearly EPS VS EstimatesALKS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 4 6

5

4. ALKS Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 15.81, which indicates a correct valuation of ALKS.
  • ALKS's Price/Earnings ratio is rather cheap when compared to the industry. ALKS is cheaper than 94.59% of the companies in the same industry.
  • The average S&P500 Price/Earnings ratio is at 25.79. ALKS is valued slightly cheaper when compared to this.
  • The Forward Price/Earnings Ratio is negative for ALKS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 15.81
Fwd PE N/A
ALKS Price Earnings VS Forward Price EarningsALKS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, ALKS is valued cheaply inside the industry as 94.79% of the companies are valued more expensively.
  • 97.88% of the companies in the same industry are more expensive than ALKS, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 9.44
EV/EBITDA 13.32
ALKS Per share dataALKS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8 10

4.3 Compensation for Growth

  • ALKS has a very decent profitability rating, which may justify a higher PE ratio.
  • A cheap valuation may be justified as ALKS's earnings are expected to decrease with -2.65% in the coming years.
PEG (NY)N/A
PEG (5Y)0.5
EPS Next 2Y-28.08%
EPS Next 3Y-2.65%

0

5. ALKS Dividend Analysis

5.1 Amount

  • ALKS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

ALKS Fundamentals: All Metrics, Ratios and Statistics

ALKERMES PLC

NASDAQ:ALKS (3/18/2026, 8:00:00 PM)

Premarket: 27.37 +0.17 (+0.63%)

27.2

-0.45 (-1.63%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25
Earnings (Next)04-29
Inst Owners109.8%
Inst Owner Change2.03%
Ins Owners1.6%
Ins Owner Change5.8%
Market Cap4.53B
Revenue(TTM)1.48B
Net Income(TTM)241.66M
Analysts81.67
Price Target44.69 (64.3%)
Short Float %11.17%
Short Ratio8.71
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)21.45%
Min EPS beat(2)-16.95%
Max EPS beat(2)59.84%
EPS beat(4)3
Avg EPS beat(4)31.82%
Min EPS beat(4)-16.95%
Max EPS beat(4)72.36%
EPS beat(8)4
Avg EPS beat(8)15.4%
EPS beat(12)7
Avg EPS beat(12)24.7%
EPS beat(16)10
Avg EPS beat(16)139.34%
Revenue beat(2)1
Avg Revenue beat(2)3.48%
Min Revenue beat(2)-1.55%
Max Revenue beat(2)8.51%
Revenue beat(4)2
Avg Revenue beat(4)4.47%
Min Revenue beat(4)-1.55%
Max Revenue beat(4)12.13%
Revenue beat(8)3
Avg Revenue beat(8)2.64%
Revenue beat(12)6
Avg Revenue beat(12)3.42%
Revenue beat(16)9
Avg Revenue beat(16)2.75%
PT rev (1m)0%
PT rev (3m)-0.14%
EPS NQ rev (1m)-476.76%
EPS NQ rev (3m)-596.9%
EPS NY rev (1m)-141.15%
EPS NY rev (3m)-140.46%
Revenue NQ rev (1m)3.82%
Revenue NQ rev (3m)0.52%
Revenue NY rev (1m)-0.87%
Revenue NY rev (3m)-1.66%
Valuation
Industry RankSector Rank
PE 15.81
Fwd PE N/A
P/S 3.07
P/FCF 9.44
P/OCF 8.7
P/B 2.49
P/tB 2.61
EV/EBITDA 13.32
EPS(TTM)1.72
EY6.32%
EPS(NY)-0.62
Fwd EYN/A
FCF(TTM)2.88
FCFY10.6%
OCF(TTM)3.12
OCFY11.49%
SpS8.86
BVpS10.92
TBVpS10.41
PEG (NY)N/A
PEG (5Y)0.5
Graham Number20.55
Profitability
Industry RankSector Rank
ROA 9.72%
ROE 13.28%
ROCE 13.07%
ROIC 10.9%
ROICexc 15.63%
ROICexgc 16.66%
OM 17.21%
PM (TTM) 16.37%
GM 86.69%
FCFM 32.55%
ROA(3y)14.74%
ROA(5y)6.76%
ROE(3y)22.64%
ROE(5y)9.68%
ROIC(3y)18.21%
ROIC(5y)N/A
ROICexc(3y)43.15%
ROICexc(5y)N/A
ROICexgc(3y)50.12%
ROICexgc(5y)N/A
ROCE(3y)21.84%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.55%
GM growth 5Y0.92%
F-Score6
Asset Turnover0.59
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 148.79%
Cap/Sales 2.74%
Interest Coverage 250
Cash Conversion 185.24%
Profit Quality 198.76%
Current Ratio 3.55
Quick Ratio 3.19
Altman-Z 5.26
F-Score6
WACC7.7%
ROIC/WACC1.42
Cap/Depr(3y)110.09%
Cap/Depr(5y)83%
Cap/Sales(3y)2.59%
Cap/Sales(5y)2.72%
Profit Quality(3y)136.19%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-40.76%
EPS 3Y71.6%
EPS 5Y31.92%
EPS Q2Q%-72.38%
EPS Next Y-135.86%
EPS Next 2Y-28.08%
EPS Next 3Y-2.65%
EPS Next 5Y31.8%
Revenue 1Y (TTM)-5.25%
Revenue growth 3Y9.9%
Revenue growth 5Y7.28%
Sales Q2Q%-10.57%
Revenue Next Year21.99%
Revenue Next 2Y12.92%
Revenue Next 3Y10.71%
Revenue Next 5Y11.16%
EBIT growth 1Y-39.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year50.82%
EBIT Next 3Y26.72%
EBIT Next 5Y26.75%
FCF growth 1Y18.41%
FCF growth 3YN/A
FCF growth 5Y63.91%
OCF growth 1Y18.59%
OCF growth 3Y191.61%
OCF growth 5Y44.45%

ALKERMES PLC / ALKS Fundamental Analysis FAQ

What is the fundamental rating for ALKS stock?

ChartMill assigns a fundamental rating of 6 / 10 to ALKS.


What is the valuation status of ALKERMES PLC (ALKS) stock?

ChartMill assigns a valuation rating of 5 / 10 to ALKERMES PLC (ALKS). This can be considered as Fairly Valued.


Can you provide the profitability details for ALKERMES PLC?

ALKERMES PLC (ALKS) has a profitability rating of 7 / 10.


Can you provide the expected EPS growth for ALKS stock?

The Earnings per Share (EPS) of ALKERMES PLC (ALKS) is expected to decline by -135.86% in the next year.